Pfizer abandons obesity pill after liver injury in setback
Pfizer will stop developing an obesity pill that has been closely watched by investors, a severe blow in its efforts to compete with blockbuster weight-loss shots from Novo Nordisk…
More from New York Business
Crain's New York Business
'Naked Gun' star Liam Neeson sells UWS apartment for $10.3M
New York Business
•
Aug 6, 2025
Crain's New York Business
Westchester and Long Island drive growth in New York's medical outpatient market
New York Business
•
Aug 6, 2025
Crain's New York Business
Teaneck hospital spends $10M to kick of multi-year development
New York Business
•
Aug 6, 2025
Crain's New York Business
Northwell's $2B Lenox Hill expansion heads for key vote
New York Business
•
Aug 6, 2025
Country Folks
Crop Comments: Should the Chicago Board of Trade Deal in Hay Futures?
New York Business
•
Aug 6, 2025
Crain's New York Business
Pfizer lifts profit view as cuts offset flat sales outlook
New York Business
•
Aug 6, 2025
Crain's New York Business
Vornado looks to sell Chicago and San Francisco office buildings, doubling down on New York
New York Business
•
Aug 5, 2025